Skip to content
Open access

Olink proteomics identifies serum protein biomarkers and an age-stratified diagnostic model for diabetes in Chinese patients

Aug 2026 · Frontiers in Endocrinology · Vol 17 · 0 citations · 48 references
Medicine

TL;DR

This study identified novel T2DM-associated plasma biomarkers and established a robust three-protein signature (VSIG2, S100A11, S100A5) for age stratification and biological senescence evaluation in T2DM.

Abstract

Background Aging is a critical risk factor for the progression and complications of type 2 diabetes mellitus (T2DM). However, routine clinical indicators fail to accurately quantify biological senescence burden in T2DM patients. This study aimed to screen plasma protein signatures associated with metabolic senescence in T2DM using Olink targeted proteomics and to construct a novel biological aging evaluation model for diabetic populations. Methods A total of 21 healthy controls and 66 T2DM patients were enrolled. Plasma protein profiles were detected via Olink proteomics. Differentially expressed proteins (DEPs) were identified and subjected to GO and KEGG functional enrichment analyses. Random forest and LASSO regression analyses were applied to screen core T2DM-related protein molecules. T2DM patients were further stratified by a 55-year cutoff, a well-recognized critical threshold for metabolic senescence. After adjustment for sex, BMI, glycated hemoglobin (HbA1C), and hypoglycemic medication use, age-independent senescence-related proteins were identified to establish a multi-protein predictive model. A 1000-time Bootstrap resampling procedure was performed for internal validation to evaluate model discrimination and stability. Results A total of 84 DEPs (P < 0.05) were identified between T2DM patients and healthy controls, mainly enriched in cytokine–cytokine receptor interaction, lipid metabolism, and atherosclerosis pathways. Machine learning screened six core proteins with high discriminatory value for T2DM, including MERTK, BOC, TNFRSF10A, CCL3, AGRP, and PD-L2. Within the T2DM cohort, nine age-dependent plasma proteins were independently identified (FDR < 0.05), among which VSIG2, LPL, S100A11, and CST5 exhibited the most robust correlations (FDR < 0.01). A three-protein model comprising VSIG2, S100A11, and S100A5 achieved favorable discriminative performance (AUC = 0.874), which was superior to conventional clinical indicators including BMI (AUC = 0.572) and HbA1c (AUC = 0.593). Bootstrap validation confirmed reliable model stability with a correction optimism of −0.024, a bias-corrected AUC of 0.900, and an overfitting degree of −2.65%. Functional analyses indicated that candidate proteins were primarily involved in immune homeostasis, lipid remodeling, inflammatory responses, and calcium signaling. Conclusion This study identified novel T2DM-associated plasma biomarkers and established a robust three-protein signature (VSIG2, S100A11, S100A5) for age stratification and biological senescence evaluation in T2DM. The proposed model compensates for the limitations of routine clinical indices, providing a promising non-invasive serological tool for precise risk stratification and individualized intervention in elderly diabetic patients.

Read PDF

Similar papers

Open access Sep 2026

Prediction of Type 2 Diabetes using genomics and proteomics: the HUNT Study (ProtRS for T2D)

Type 2 diabetes (T2D) is a multifactorial metabolic disorder with an increasing global prevalence and significant health burdens. Early identification of individuals at high risk is crucial for timely intervention and prevention of T2D and complications. This study aims to investigate the association between the blood...

Fikria Karinanur, B. Åsvold, G. Giskeødegård et al. · 0 citations
Open access Sep 2026

Circulating PCSK9: A new frontier in cancer risk stratification for obese diabetics.

This study investigated potential plasma biomarkers associated with cancer risk and mortality in patients with type 2 diabetes mellitus (T2DM), a population known to have an increased cancer incidence and poorer outcomes compared with non-diabetic individuals. Traditional metabolic indicators, including blood pressure,...

Lien-Cheng Tsao, Chen-Ling Kuo, Yu-Shan Cheng et al. · 0 citations
2026

A lipid metabolism–based gene signature defines diagnosis and molecular heterogeneity in diabetic nephropathy

Objective(s): To identify lipid metabolism-related biomarkers of diabetic nephropathy (DN), develop and validate a diagnostic model, and further explore immune infiltration patterns and molecular subtypes of DN. Materials and Methods: Multiple public transcriptomic datasets were integrated to identify lipid metabolism-...

Qing-Bu Mei, Xin-Yu Liu, Jing Xu et al. · 0 citations
Open access Sep 2026

Proteomic signatures of systemic inflammation in aging, multimorbidity, and mortality.

BACKGROUND Chronic low-grade inflammation is central to biological aging, but routine inflammatory biomarkers capture limited molecular heterogeneity. We aimed to develop a proteomic inflammaging score (PIS) and evaluate its practical utility. METHODS In 40,471 England participants from UK biobank, we used LASSO to i...

Zhou Jiang, Dan-Yang Ling, Zi-Wei Chen et al. · 0 citations
Open access Sep 2026

Integrative identification and preliminary validation of senescence-associated secretory phenotype-related candidate biomarkers in type 2 diabetes

Senescence-associated secretory phenotype (SASP)-related inflammatory programs have been implicated in type 2 diabetes mellitus (T2DM), yet blood-based candidates have not been systematically screened and validated across independent cohorts. We adopted standardized senescence signature scoring and multi-cohort indepen...

Bing-Lian Liu, Jia-Meng Jia, Nan Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.